Summary of Haemonetics Conference Call Company Overview - **Company**: Haemonetics - **Industry**: Medical Technology (MedTech) - **Revenue**: Approaching $1.4 billion, diversified small midcap MedTech company - **Market Leadership**: Global leader in plasma apheresis with a billion-dollar addressable market [2][3] Key Financial Performance - **Fiscal Year Performance**: - High single-digit revenue growth - Operating margin expansion of over 800 basis points - Cumulative free cash flow of $600 million to $700 million - Added $3 in earnings per share over the four-year long-range plan (LRP) [3] Plasma Business Insights - **Growth**: Plasma segment grew 3% organically, 20% excluding CSL [4] - **Drivers of Growth**: - Sustained share gains - Innovation-led platform benefits - Increased collection strength [5] - **Persona PLUS Launch**: - Mid-single digit yield increase compared to Persona - Built on data-driven approach with a pivotal trial involving over 30,000 plasma donations [6][8] Customer Relationships and Market Position - **Customer Engagement**: Strong relationships leading to share gains and deeper strategic partnerships [10] - **Market Leadership**: Expectation to grow global marketplace leadership for the foreseeable future [12] Competitive Landscape - **Competitors**: Mention of Terumo's Rika and other competitors, with emphasis on Haemonetics' integrated platform and lower cost metrics [13][14] - **NexSys and Persona PLUS**: Positive reception from customers, leading to standardization around Haemonetics' technology [10] Interventional Technologies and Vascular Closure - **Challenges**: Acknowledgment of challenges in the vascular closure space but confidence in returning to above-market growth [19][20] - **Market Dynamics**: Shift to Ambulatory Surgical Centers (ASCs) and increased adoption of PFA expected to favor Haemonetics [21] - **Product Launches**: - MVP label expansion in the U.S. and Japan - Vivasure acquisition leading to the launch of PerQseal Elite [21][27] Blood Management Technologies - **Growth Potential**: Blood management technologies, particularly TEG, showing consistent double-digit growth with significant market penetration opportunities [33][34] - **Market Size**: Global Serviceable Available Market (SAM) for TEG estimated at over $400 million, with less than 50% penetration [34] Capital Deployment Strategy - **Focus on Organic Growth**: Prioritizing R&D and commercial execution for competitive advantage [43] - **Debt Management**: Addressed $300 million debt maturity using revolver, maintaining capital structure efficiency [44] - **Share Repurchases**: Attractive risk-adjusted returns at current share prices, with plans for opportunistic capital deployment [44] Margin Improvement - **Current Margins**: Operating income margin increased from 13% to 26% over the past decade, with aspirations for further improvement [48][49] - **Future Expectations**: Anticipation of continued margin expansion driven by operational improvements and product mix [49] Outlook for FY27 - **Growth Expectations**: Balanced, sustainable growth with continued revenue growth, margin expansion, and free cash flow [53] Conclusion - **Company's Position**: Haemonetics is positioned for future growth with a strong focus on innovation, customer relationships, and market leadership in plasma and blood management technologies [55]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [17][18] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with strong performance in Blood Management Technologies offsetting softness in Interventional Technologies [6][9] - Blood Management Technologies grew 8% in the quarter and 11% year-to-date, driven by strong sales of TEG 6s disposables and the heparinase neutralization cartridge [6][7] - Interventional Technology revenue declined 12% in the quarter and 8% year-to-date, primarily due to softness in esophageal cooling and OEM-related headwinds [8][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter and 22% year-to-date, driven by share gains and collection volume [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - Blood Center revenue was $57 million in the quarter, growing 3% in the quarter and 4% year-to-date organically, driven by international plasma demand [10][11] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivasure is expected to enhance the company's leadership in vascular closure, with a $300 million addressable market identified [43][46] - Capital allocation priorities include investing in organic growth, meeting debt obligations, and opportunistically returning cash to shareholders while maintaining balance sheet flexibility [22][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][31] - Management remains optimistic about the growth potential in the vascular closure market, particularly with the anticipated MVP XL label expansion [38][59] Other Important Information - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [11] - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [15] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin expectations and challenges in the hospital business - Management acknowledged a sequential decline in adjusted operating margin but expressed confidence in overall margin expansion moving forward [30][31] Question: Updates on the IVT business and competition - Management noted that a significant portion of the decline in IVT was due to specific market dynamics, but they are confident in their strategy to return to growth [36][38] Question: Details on the Vivasure acquisition and market positioning - Management emphasized the strategic importance of Vivasure in enhancing their vascular closure portfolio and outlined a measured approach to its market launch [43][46] Question: Sustainability of blood center growth - Management indicated that while the blood center business has shown positive growth, it is subject to order timing and market conditions [79]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [18][19] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [6][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth excluding CSL at 20% in the quarter [9][10] - Blood Center revenue was $57 million in the quarter, growing 3% and 4% year-to-date organically, driven by international plasma demand [10][11] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - The vascular closure market is experiencing headwinds from increasing PFA adoption, which is affecting growth rates in the electrophysiology market [58][60] Company Strategy and Development Direction - The company is focused on returning the interventional technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivisure is expected to enhance the company's position in vascular closure, with a market potential of approximately $300 million [44][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, citing strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][32] Other Important Information - The company raised its full-year revenue guidance, expecting a decline of 1%-3% from a previous range of 1%-4% [11] - Cash on hand at the end of the third quarter was $363 million, up 18% since the start of the fiscal year [19] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin outlook and hospital business challenges - Management acknowledged a sequential decline in adjusted operating margin but expressed optimism about stabilization in the hospital business [28][30] Question: IVT business recovery and competition - Management noted that a significant portion of the decline in IVT was due to specific product disruptions, but they are confident in returning to growth [36][38] Question: Vivisure acquisition details - Management emphasized the strategic importance of Vivisure and its potential to enhance the vascular closure portfolio [44][48] Question: Capital deployment strategy - Management outlined a disciplined approach to capital deployment, prioritizing organic growth and debt reduction while maintaining flexibility for future investments [47][48]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [4][10] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [5][14] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, driven by the adoption of NexSys technology and divestiture of the Whole Blood business [11][12] - Free cash flow for the third quarter was $74 million, with year-to-date free cash flow reaching $165 million, representing a threefold increase compared to the prior year [15][16] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [5][6] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter, driven by share gains and collection volume [8][9] - Blood Center revenue was $57 million in the quarter, growing 3% organically, primarily due to international plasma demand [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [8][9] - The hospital business is expected to deliver reported and organic growth of approximately 4% at the low end of the prior 4%-7% range [7][10] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen this segment [18][19] - The Vivisure acquisition is expected to enhance the company's leadership in vascular closure, with a market opportunity estimated at $300 million [44][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong relationships and a favorable market environment [24][26] - The company anticipates continued margin expansion and strong cash flow generation, with a focus on disciplined capital deployment [15][21] Other Important Information - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [13][14] - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [10][11] Q&A Session Summary Question: Can you provide insights on plasma collections and market growth? - Management indicated that share gains and collection volume are driving growth, with double-digit increases in both U.S. and international collections [24][25] Question: What are the expectations for margins moving forward? - Management expects smaller increments in margin improvements in the future, with ongoing focus on operational efficiency [29][30] Question: What is the status of the IVT business and competition? - Management noted that 70% of the decline in IVT was due to specific market disruptions, but they are confident in returning to growth with the right strategies in place [35][36] Question: Can you elaborate on the Vivisure acquisition and its market potential? - The acquisition is seen as a significant opportunity to enhance the company's position in vascular closure, with a focus on a stepwise approach to market entry [44][47] Question: How is the company addressing the challenges in the hospital business? - Management highlighted strong performance in blood management technologies and a focus on stabilizing the IVT segment as key to future growth [81][82]

Summary of Artivion (AORT) Conference Call Company Overview - **Company**: Artivion (AORT) - **Industry**: Medical Devices, specifically focused on aortic treatments Key Points and Arguments Market Potential and Growth Strategy - Artivion operates in multiple Total Addressable Markets (TAMs) that, while individually smaller, collectively provide a durable growth runway [2][4] - The company is focused on the aortic segment, particularly advanced stent grafts, with a global market for stents and stent grafts estimated at $4 billion, of which $2 billion is in advanced stent grafts [5][6] - Artivion's pipeline includes several products with upcoming PMA submissions, including AMDS, NexSys, and Arecibo, which are expected to contribute to growth every 18 months [9][10] Product Pipeline and Innovations - **AMDS**: Expected PMA approval by mid-2026, with a TAM of over $500 million [12][13] - **NexSys**: A pivotal trial with 60 patients showed promising results, with a focus on chronic dissections [32][33] - **Arecibo**: A product for total replacement of the aortic arch, with trials expected to start later this year [8] - The company has a unique patented technology for aortic dissection that significantly reduces mortality rates [15][16] Financial Performance and Projections - Artivion aims for EBITDA growth at twice the rate of top-line growth, driven by margin expansion and operational efficiencies [69][71] - The company has successfully reduced leverage and improved cash flow, with a focus on maintaining reasonable debt levels while funding growth initiatives [45][46] Sales and Market Penetration - The existing sales force is deemed adequate for launching new products, with no immediate plans for expansion [21][22] - The company is actively working with over 150 accounts to navigate hospital bureaucracy for product adoption [23][24] Risks and Challenges - The primary risk to growth acceleration is the timing of hospital bureaucracy related to product adoption [68] - The company experienced a cyber attack that impacted supply chains, but recovery is expected by the end of Q3 [63][66] Competitive Landscape - Artivion's On X mechanical valve has shown a 14% CAGR over the past eight years, with a TAM of $250 million [54] - Recent studies indicate a mortality benefit for mechanical valves, opening up additional market opportunities [58][61] Conclusion - Artivion is positioned for significant growth in the aortic medical device market, with a strong pipeline of innovative products and a focus on operational efficiency and margin expansion. The company is navigating challenges related to market entry and hospital adoption but remains optimistic about future performance.